Autoimmune Diseases · 2014 · 22 citations · 13 references
Life SciencesImmunologyPharmacotherapyAutoimmunityClinical ImmunologyRheumatologyAutoimmune DiseasesChronic InflammationImmunosuppressionImmunosuppressive TherapyMaintenance TherapySystemic Lupus ErythematosusDisease Remission InductionImmunosuppressive Drug TherapyObservational Study AnalysisRemission Induction TherapyRituximab-based Therapy
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with rituximab (RTX) as remission induction therapy and maintenance. There was a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease. RTX appeared to be effective and safe for the induction and maintenance of remission in patient with SLE refractory to conventional treatment.
13
The 1982 revised criteria for the classification of systemic lupus erythematosus
Eng M. Tan, Alan S. Cohen, James F. Fries et al. · Arthritis & Rheumatism · 1982 · 14.6K citations
Derivation of the sledai. A disease activity index for lupus patients
Claire Bombardier, Dafna D. Gladman, Murray B. Urowitz et al. · Arthritis & Rheumatism · 1992 · 4.6K citations
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
John H. Stone, Peter A. Merkel, Robert Spiera et al. · New England Journal of Medicine · 2010 · 2.7K citations · Full text